著名血浆蛋白生产商CSL Behring公司最近和俄亥俄州的医疗设备生产公司Enable Injections公司签订合作协议共同开发用于治疗慢性疾病的药物输送系统。这也使得CSL公司得以正式试水医疗器械领域。

长期以来，CSL公司一直致力于血友病、免疫缺陷病、肺气肿和一些治疗烧伤、心脏病的药物疗法的开发。但是由于这些药物的主要活性成分都是人血浆蛋白，因此需要找到合适的载药系统输送进入人体才能起到合适的疗效。

作为一家主要生产可佩带注射器的生物技术公司，Enable公司在这一领域具有丰富的经验。公司开发的新型注射设备能够在向病人体内注射药物前自动混合相关药物并对药物进行预加热，以免患者产生不适。同时这一设备还具有显示屏以帮助患者了解药物的注射进度并可以随时停止注射进程。患者只需要将这一设备佩戴在身上并按下按钮，就可以自动接受给药治疗。

Enable公司的CEO Mike Hooven在声明中表示，慢性疾病患者面临着周期性治疗的问题，而这一问题也影响了这些慢性病患者的生活质量。而公司开发的这种治疗设备能够使这一治疗过程程序化并降低医生的工作量，使得患者在治疗过程中更安全、更便捷。与CSL公司的合作有效的促进了公司进一步推广这一设备。

不过合约双方并未透露此次协议设计的金额，CSL公司仅表示已经向Enable公司预付了部分费用，同时协议中还包括了里程碑奖金和版权等内容。（生物谷Bioon.com）

Plasma protein specialist CSL Behring has tied the knot with Ohio devicemaker Enable Injections to use Enable's technology for the delivery of treatments for chronic diseases. The development agreement will give CSL access to market the device.

CSL, which makes therapies for chronic conditions such as hemophilia, immune deficiencies and emphysema, as well as critical care drugs for shock, sepsis and burns, derives its products from human plasma or equivalents thereof. Because of the viscosity and volume of the plasma needed to treat these conditions, it takes a specific kind of delivery device to make it work.

Enter Enable, which has developed a wearable bolus injector that allows the subcutaneous injection of biological drugs. The system incorporates a closure for a vial, syringe or cartridge that automatically mixes the solutions, warming the drug so that the patient doesn't have to wait for a refrigerated mixture to be ready for injection. The patient places the device on his or her skin and presses a button. The device has a viewing window to show the injection's progress, a "pause" feature and an automatically retracting needle.

"People with chronic diseases have to routinely manage their condition," Enable CEO Mike Hooven said in a statement. "Our innovative drug delivery system makes administering a life-long treatment easier and much more convenient. We are thrilled to partner with a scientific leader like CSL Behring to, upon regulatory approvals, bring this device to patients in the rare disease community who may benefit from our innovative drug delivery system."

The terms of the partnership have not been disclosed, except for CSL's exclusive use of the product and Enable's receipt of an upfront payment with milestone and royalty payments over the next several years.

"Through our collaboration with Enable Injections," CSL Executive Vice President Bob Repella said, "we hope to bring patients a delivery option that makes administration of their therapy easier, helps improve treatment compliance and offers them greater freedom and flexibility to treat their condition in a way that fits their individual needs."